Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M3XzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvGW2lHPcLizszN MnHFOFjDqGh? MXnicI9kc3NiMketU2hENWmwZIXj[YQh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDhdoFjdGVidH:geIhifCCxZjDiZZNidCCuZY\lcJM> MlzoNlY{PTB3NkW=
NP69 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPKT2tKSzVyPUOxMlY6yrF{LkW0JO69VQ>? MkXENlYzPTJ3N{W=
NP460 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzoW5dqUUN3ME2yNk45PcLzMT6xPEDPxE1? NYT2SYhxOjZ{NUK1O|U>
C666-1 NWnDPJJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvQTWM2OD1zOT65OeKyQC57MzFOwG0> NIGxXW8zPjJ3MkW3OS=>
C666-1 MmP1R4VtdCCYaXHibYxqfHliQYPzZZk> MoW0NVAhyrWP MlHaOFghcA>? M2HqVWROW09? NF;yOml{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{B1cGViY4n0c5RwgGmlIHXm[oVkfCCxZjDjbZNxdGG2aX6= NHvFWJkzPjJ3MkW3OS=>
C666-1  NV7ZN48yTnWwY4Tpc44hSXO|YYm= M4q2UFExKML3TR?= MVKyOEBp MUfEUXNQ M1jl[YFkfGm4YYTld{B1cGVicEWzJJBifGi5YYmsJJVxemWpdXzheIlv\yCyNUOsJJAzOSCjbnSgUYRuOg>? NEHPPFIzPjJ3MkW3OS=>
C666-1 NYXQfHJySXCxcITvd4l{KEG|c3H5 Mn\lNVAhyrWP M1exc|Q5Nzd{IHi= NX;uXGZNTE2VTx?= MnXzd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:gZ4l{eGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz M4XqOlI3OjV{NUe1
A549 NEDHc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOyOEBp NXvNVYRQUUN3ME2xO{43QCEEsTC0MlUzKM7:TR?= NX\RXZhjOjZzMkWyN|A>
A549-NTC MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2yOEBp NHLvWVVKSzVyPUG5MlQzKMLzIEGuPVYh|ryP MWGyOlEzPTJ|MB?=
A549-920 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml[yNlQhcA>? M4X3OGlEPTB;M{OuPFUhyrFiND64OEDPxE1? MX[yOlEzPTJ|MB?=
CRL-5908 NFzXXGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLEc|gzPCCq NXz2PIttUUN3ME2zPE44OSEEsTCyMlQ{KM7:TR?= M33nNlI3OTJ3MkOw
L6 M{fEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fBO|ExyqEQvF5CpC=> MnjpNlQwPDhxN{KgbC=> NUT3W4kyTE2VTx?= M2jkTolvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? M2nQTVI2QDdzN{m0
C2C12 NWXzUHhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\LSJkyOMLizszNxsA> MUmyOE81QC95MjDo M1O1c2ROW09? NFHGR4lqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? M3z6TFI2QDdzN{m0
MCF-7  NFPTXYVHfW6ldHnvckBCe3OjeR?= Ml:zNVDDqM7:TR?= NWfveXV2TE2VTx?= M1vMcIlvcGmkaYTzJIN6[2yrbjDENUBidmRiRHnj[ZLDqA>? NXPYWWd[OjV5MEK3NFM>
DU4475  NGjSVo1HfW6ldHnvckBCe3OjeR?= Mny4OU8yOC9{MDFOwG0> NH7LO4MzPMLiaB?= NFTqOWlld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 NH63PWYzPTV2N{G3OC=>
SMMC-7721 MXXGeY5kfGmxbjDBd5NigQ>? NFvvRnQyOCEQvF2= M2XKSlQ5KGh? NF:1fHBFVVOR NIDFTplk[XW|ZYOgSG5CKESVQjDkZY1i\2V? MoH3NlU2PDR|NkG=
SMMC-7721 NV;i[GNUTnWwY4Tpc44hSXO|YYm= MoHuNVAh|ryP MXO0PEBp NIPifGRFVVOR MmLHbY5lfWOnczD0bIUh[2i{b33heIlvNWKxdX7kJJBzd3SnaX6gTWZKOTZidH:gdIFzfGmjbHz5JIxw[2GuaYrlJIlvKHSqZTDjfZRweGyjc35CpC=> NIjjNZUzPTV2NEO2NS=>
SMMC-7721 MojlSpVv[3Srb36gRZN{[Xl? M3nCc|ExKM7:TR?= Ml;ROFghcA>? M{TzeGROW09? MnjQbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=> MmDUNlU2PDR|NkG=
SMMC-7721 MX7GeY5kfGmxbjDBd5NigQ>? Mmi2NVAh|ryP NY\lNmI1OzZiaB?= NGDscnBFVVOR NIHW[|Fk[XW|ZYOgeIhmKGWldH;wbYMh\XiycnXzd4lwdiCxZjDJSmkyPg>? MXSyOVU1PDN4MR?=
MCF-7 NVTlSnE6TnWwY4Tpc44hSXO|YYm= M{P2RlExyqEQvF2= NUXJ[VRQOC1{NDDo NXvVVYFLcW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx MkfBNlU1QDJ|N{O=
OVCAR10 NILzb3JHfW6ldHnvckBCe3OjeR?= M3HLZVExyqEQvF2= MmD3NlFpyqB? NWX5RppZTE2VTx?= NFLVS2lqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ MYOyOVQzPjV2OB?=
NCI-H23 M2TpPGZ2dmO2aX;uJGF{e2G7 NIfKbmoyOMLizszN MmfNNlFpyqB? MXzEUXNQ NWDyeIxMcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NXjjVGx[OjV2Mk[1OFg>
A2780 NVvFeXFFTnWwY4Tpc44hSXO|YYm= M2W5bVExyqEQvF2= MV:yNYjDqA>? MkTmSG1UVw>? NX:yUotIcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? NU[3PIg2OjV2Mk[1OFg>
NCI-H23 NVP3fIpYTnWwY4Tpc44hSXO|YYm= NF3WNlUyOMLizszN NHfnVnAzOWkEoB?= MW\EUXNQ NGLIXWhl\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> Mnj0NlU1OjZ3NEi=
A2780 NFv1V3dHfW6ldHnvckBCe3OjeR?= M2DxRlExyqEQvF2= NX7aXI53OjGqwrC= M4\TcGROW09? NVfPZpBH\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> M3jU[VI2PDJ4NUS4
HCT116  MYDGeY5kfGmxbjDBd5NigQ>? MYmxNEDDvU1? NFHXd5MzPCCq Ml3uZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 NXPnXlVFOjV|OECwOVU>
MCF-10CA1a M3;1[GZ2dmO2aX;uJGF{e2G7 MVqxNOKh|ryP MnfhOFghcA>? MXHEUXNQ MlvIbY5pcWKrdIOgZoF{[WxiaX72ZZNqd25iYX7kJJJm\HWlZXSgWGdHNc7{Mz3pcoR2[2WmIHnueoF{cW:wIITvJIJie2GuIHzleoVtew>? MkTkNlUzPTd5Mkm=
MCF-10A1  M1\6UGZ2dmO2aX;uJGF{e2G7 NWi0b5VnOTEEoN88US=> NHPyTlYzPC92ODDo NGrRSpVFVVOR NHTRNXlqdmirYnn0d{BucWe{YYTpc44hd2Zibn;ycYFtKGK{ZXHzeEBmeGm2aHXsbYFtyqB? NXnjdnJPOjV{NUe3Nlk>
MCF-10CA1a M3q1T2Z2dmO2aX;uJGF{e2G7 MX6xNOKh|ryP M4fBVVI1KGh? NXm4ZppoTE2VTx?= NVK0bG41\GWlcnXhd4V{KHSqZTDUS2Yu|rJ|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh|rMEoEO= M{CzU|I2OjV5N{K5
MCF-10CA1a M{XndmZ2dmO2aX;uJGF{e2G7 NVPye5hPOTEEoN88US=> MXmyOEBp MXnEUXNQ NFLmOI9qdmirYnn0d{AhXEeILd8yN{1qdmS3Y3XkJGVRUEJ{wrDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= MXKyOVI2Pzd{OR?=
SK-BR-7 M4rJN2Z2dmO2aX;uJGF{e2G7 MXWxNOKh|ryP MWeyOEBp MWfEUXNQ M4DFS4lvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NXL0T|gyOjV{NUe3Nlk>
SUM102PT NV7a[ZlNTnWwY4Tpc44hSXO|YYm= M3ryVFExyqEQvF2= M1vsTlI1KGh? NWLqfVJPTE2VTx?= M1TjV4lvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NXu0ZYh7OjV{NUe3Nlk>
RAW 264.7 NWLRPW9LTnWwY4Tpc44hSXO|YYm= MXixNOKh|ryP NH\4W40{OCCvaX6= MojMdJJmfmWwdIOgeIhmKHB3MzDy[YR2[3Srb36gbY4hemW|cH;ud4UhfG9iTGDT M2nOZlI2OTd{NUS3
RAW 264.7 NVS3OWVVTnWwY4Tpc44hSXO|YYm= MVOxNOKh|ryP MlfxN|AhdWmw MVTy[YR2[2W|IITo[UBNWFNvYYXncYVvfGWmIITo[UBPTi4QulKgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHjeIl3cXS7 MljkNlUyPzJ3NEe=
RAW 264.7 M3jzXmZ2dmO2aX;uJGF{e2G7 MWWxNOKh|ryP NXzZPFJPOzBibXnu NEXOc2VqdmirYnn0d{BNWFNvaX7keYNm\CCQTzDwdo9lfWO2aX;uxsA> NUi3SJRZOjVzN{K1OFc>
MCF7  MoH6R4VtdCCYaXHibYxqfHliQYPzZZk> MUCyMlUhyrWP NG\KWlM2KGR? NWPpV|c2TE2VTx?= M{jmSpNmdnOrdHn6[ZMhVUOINzD0c{BRSVKSIHnubIljcXSrb36= MX:yOVA5PTlyMh?=
MCF7  Mm\MSpVv[3Srb36gRZN{[Xl? MWqyMlUhyrWP NYP1NlJnPDhiaB?= M2mzUGROW09? NF[4UlJl\WO{ZXHz[ZMhfGinIHjvcY9td2exdYOgSHNDKHKncHHpdkBnemWzdXXuZ4lmew>? NIHlbZEzPTB6NUmwNi=>
ACHN MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWKwMlUuOTBizszN NG[w[44xNTZiZB?= NXj4c4tyTE2VTx?= MXrpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFf3[Y8zPTB4N{e4Oy=>
Caki-2 M1;OfmNmdGxiVnnhZoltcXS7IFHzd4F6 Ml\1NE42NTFyIN88US=> M1ewVVAuPiCm NI\1cYNFVVOR M3zRVIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M3zCTVI2ODZ5N{i3
A498 NIXXPWFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV6wMlUuOTBizszN MmHnNE03KGR? NX\0c5JxTE2VTx?= M1\DZolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1G3WlI2ODZ5N{i3
115 NFTBb2xE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGfrS4gxNjVvMUCg{txO MV6wMVYh\A>? NIXtSFVFVVOR M2TTUIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NGPzT2gzPTB4N{e4Oy=>
117 M4XrXmNmdGxiVnnhZoltcXS7IFHzd4F6 NGLMSlQxNjVvMUCg{txO Mke4NE03KGR? NXjobnBGTE2VTx?= M2rXVolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWOyOVA3Pzd6Nx?=
ACHN NETQbFZHfW6ldHnvckBCe3OjeR?= MmGzNE42NzFxNTFOwG0> MnPGOFghcA>? MVHEUXNQ NEj4Z2pt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= M2ftXlI2ODZ5N{i3
Caki-2 NIO2dpNHfW6ldHnvckBCe3OjeR?= MYSwMlUwOS93IN88US=> Ml;OOFghcA>? MVzEUXNQ MkTZcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? MoXONlUxPjd5OEe=
A498 M1zsemZ2dmO2aX;uJGF{e2G7 M2jZ[VAvPS9zL{Wg{txO MX20PEBp MV;EUXNQ NGnkfmFt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MUKyOVA3Pzd6Nx?=
115 M3jLRmZ2dmO2aX;uJGF{e2G7 M{fRV|AvPS9zL{Wg{txO Mlz1OFghcA>? M3zBVmROW09? M4TFO4xm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NGHDbFgzPTB4N{e4Oy=>
ACHN MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu1JO69VQ>? MYG0PEBp Mk\hSG1UVw>? MmPTbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MkPhNlUxPjd5OEe=
Caki-2 NUfQbIt5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W3N|Uh|ryP MX:0PEBp NEf6TphFVVOR M2DzOIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> M1TMWlI2ODZ5N{i3
A498 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHrOUDPxE1? NGH0e2Q1QCCq M{LCb2ROW09? MUXpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NF;vdHkzPTB4N{e4Oy=>
115 NULhR5p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPFOlA2KM7:TR?= NEX3UG81QCCq M3G4emROW09? MXjpcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2wrC= NWm4RY94OjVyNke3PFc>
ACHN MYTGeY5kfGmxbjDBd5NigQ>? M4TS[|Uh|ryP MUm0PEBp NFLMfZJFVVOR MYjpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NXK4bpAyOjVyNke3PFc>
Caki-2 MlW5SpVv[3Srb36gRZN{[Xl? NIrBNoQ2KM7:TR?= M13XS|Q5KGh? NELYdJpFVVOR NF\pZoZqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NXzVfGdjOjVyNke3PFc>
A498 M2SyUmZ2dmO2aX;uJGF{e2G7 MX21JO69VQ>? MXW0PEBp M3;xWmROW09? M{\5R4lv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= M1G2VVI2ODZ5N{i3
115 MofzSpVv[3Srb36gRZN{[Xl? NUXIbIxwPSEQvF2= NX\3TppTPDhiaB?= NV;4ZWcyTE2VTx?= NISzRo5qdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg NEjhZpczPTB4N{e4Oy=>
MOLM-13 MV7GeY5kfGmxbjDBd5NigQ>? NIj6W5U3yqEQvF2= MnTINE05KGh? MnnLSG1UVw>? M1\YS4lv[3KnYYPld{B1cGVibHX2[Yx{KG:oIIC1N{whVUSPMjygdFIyKGGwZDDhZ4V1gWyjdHXkJJA2Ow>? NVrLW4VnOjR6OEWwPFI>
MOLM-13 NFm3R5pHfW6ldHnvckBCe3OjeR?= M3nmSFbDqM7:TR?= NUDtNIREPiCq M{fjcWROW09? NELXUpFmdmijbnPld{B1cGViYXPleJlt[XSrb36gc4YhcGm|dH;u[UBJOkJiYX7kJIhm[XRic3jvZ4sheHKxdHXpcpMhUHOyMkegZY5lKEi|cEmw M3:2d|I1QDh3MEiy
HepG2 NXTnWmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fZZ|czKGh? NV[xSnF7TE2VTx?= M4i0RWlEPTB;M{WuPFYhyrFiMj65JO69VQ>? MVqyOFg5PDhyOR?=
HepG2/As M{i1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXW3NkBp MljBSG1UVw>? MnfRTWM2OD14OD6xN{DDuSB7Lk[g{txO NUm2cIFtOjR6OES4NFk>
SMMC7721 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX1bWU4OiCq MWfEUXNQ NF64ZZZKSzVyPUOxMlI5KMLzIESuNkDPxE1? MkXINlQ5QDR6MEm=
SMMC7721/Ac MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fR[|czKGh? M4LueWROW09? MUjJR|UxRTV3LkKxJOKyKDVwMEOg{txO NWD6WXpmOjR6OES4NFk>
Huh-7 NGruWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HhUVczKGh? MnTPSG1UVw>? MmXETWM2OD1|Mz65OkDDuSB|Lkmg{txO NYLyNYFCOjR6OES4NFk>
Hep3B NEnBcIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rrWVczKGh? M4TtNmROW09? Mn\DTWM2OD1{MD6xPEDDuSBzLki0JO69VQ>? NFHyNXQzPDh6NEiwPS=>
HepG2 NF35e5dCeG:ydH;zbZMhSXO|YYm= Mm\2bY5lfWOnczDhdI9xfG:|aYO= MXSyOFg5PDhyOR?=
SMMC7721 NFLHZm9CeG:ydH;zbZMhSXO|YYm= MYXpcoR2[2W|IHHwc5B1d3Orcx?= MnKwNlQ5QDR6MEm=
Huh-7 Mk\rRZBweHSxc3nzJGF{e2G7 NUH0S4RrcW6mdXPld{BieG:ydH;zbZM> Mkn5NlQ5QDR6MEm=
Hep3B NIOxe5BCeG:ydH;zbZMhSXO|YYm= Ml\MbY5lfWOnczDhdI9xfG:|aYO= M3K1VFI1QDh2OEC5
U2OS  MkDWSpVv[3Srb36gRZN{[Xl? MnvaNlAh|ryP MnK1NlQhcA>? MWnpcoNz\WG|ZYOgeIhmKG2UTlGgcIV3\Wy|IH;mxsBDS0x{QUGsJGJEVFiOwrDhcoRDS0yZ Mom2NlQ5Pjd{NUm=
AML2 M{jXPWFxd3C2b4Ppd{BCe3OjeR?= NIjZTXozNzFyIN88US=> MYCyOE81QCCq MYjpcoR2[2W|IHHwc5B1d3Orcx?= Ml3aNlQ3PTl5NEm=
MOML13 M2nNSWFxd3C2b4Ppd{BCe3OjeR?= MlmxNk8yOCEQvF2= MV2yOE81QCCq M1;Zd4lv\HWlZYOgZZBweHSxc3nz NWrXSmVJOjR4NUm3OFk>
AML2 MWTGeY5kfGmxbjDBd5NigQ>? NF7zenIyOM7:TR?= MlWxNk81KGh? MU\pcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= NWe1NmdvOjR4NUm3OFk>
AML3 M4r1bGZ2dmO2aX;uJGF{e2G7 Ml;mNVDPxE1? NGXsVFIzNzRiaB?= Mm[xbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= MXmyOFY2QTd2OR?=
MOML13 MWXGeY5kfGmxbjDBd5NigQ>? NYnmeFFkOTEQvF2= NVTBZpBJOi92IHi= MonhbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= NWm4WpNFOjR4NUm3OFk>
BeWo NX7RcY5qTnWwY4Tpc44hSXO|YYm= NF\HRoY{OCEEtV2= MVmyOEBp MVTpcoNz\WG|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy= M{TYNVI1PDl6MUW0
BeWo NGHLPJBCeG:ydH;zbZMhSXO|YYm= MVOzNEDDvU1? M33JWFI1KGh? M1TlcYlv[3KnYYPld{BieG:ydH;zbZM> M4nnN|I1PDl6MUW0
OCI MYPGeY5kfGmxbjDBd5NigQ>? Ml[0NVAh|ryP MVKyOEBp MYf1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? M{myOlI1PDd|NU[y
MOLM NFz1SXNHfW6ldHnvckBCe3OjeR?= NVfmeIJJOTBizszN MnH2NlQhcA>? MVL1dJJm\3WuYYTld{B1cGViU1;DV{0yKGW6cILld5Nqd25? NUPXfGZJOjR2N{O1OlI>
U2OS  NG\uO5NHfW6ldHnvckBCe3OjeR?= Mk\JNlAh|ryP NF70fmwzPCCq NIG3W|BqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw M2HXVFI1OzZ4MEC3
RKO NWHzdWZ5TnWwY4Tpc44hSXO|YYm= NEHkcGkzOCEQvF2= NHfkOIQzPCCq MXTpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgTG8uOSCycn;0[YlvKGG|IIflcIwh[XNidHjlJJA2OyCycn;0[Ylv NET1W|kzPDN4NkCwOy=>
U2OS  NILXenZHfW6ldHnvckBCe3OjeR?= NGe1Xo4zOCEQvF2= NUnKc|hlOjRiaB?= MmK5bY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MmGyNlQ{PjZyMEe=
RKO M3HNZWZ2dmO2aX;uJGF{e2G7 MV6yNEDPxE1? M4rYSFI1KGh? NIPlXmtqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> NV64ZXVHOjR|Nk[wNFc>
SMMC-7721  M4CyR2NmdGxiVnnhZoltcXS7IFHzd4F6 MVmxMlI2NTJyIN88US=> NVm5e2NnOjRxNEivO|IhcA>? Mlu2SG1UVw>? NUDvOHhKcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> NXnLd5pQOjR{OE[zNVI>
HuH-7 NF75TZdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWmzN|RyOS5{NT2yNEDPxE1? Ml\vNlQwPDhxN{KgbC=> MnrjSG1UVw>? NIqxXYFqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> NVHIPXVXOjR{OE[zNVI>
SMMC-7721  NXe4bIV1SXCxcITvd4l{KEG|c3H5 M{OyZlIxKM7:TR?= NV\jWJEzPDhiaB?= M2Lv[mROW09? MoHNbY5lfWOnczDhdI9xfG:|aYO= NEnMUGQzPDJ6NkOxNi=>
HuH-7 M2e4TWFxd3C2b4Ppd{BCe3OjeR?= NIG0eZMzOCEQvF2= M372bFQ5KGh? NH7uU4VFVVOR MYrpcoR2[2W|IHHwc5B1d3Orcx?= MoHHNlQzQDZ|MUK=
SMMC-7721  M3nrd2Z2dmO2aX;uJGF{e2G7 M1jEb|ExKM7:TR?= NFjSWYU{PiCq NEOwWHdFVVOR NYrxUohY\G:5bj3y[Yd2dGG2ZYOgeIhmKHC{b4TlbY4h\XiycnXzd4lwdiCuZY\lcEBw\iCyaH;zdIhwNVOnckO5Nk1xPTN? MoK1NlQzQDZ|MUK=
HuH-7 NH;N[o1HfW6ldHnvckBCe3OjeR?= MX[xNEDPxE1? MVOzOkBp Ml\VSG1UVw>? MULkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> M2DQO|I1Ojh4M{Gy
AT2 M3Xic2Z2dmO2aX;uJGF{e2G7 M3;0Z|UwOTBizszN NXuwXnFJdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MWKyOFI1ODJyMx?=
REH Mn;3SpVv[3Srb36gRZN{[Xl? NHzHVnA2NzFyIN88US=> MnPhcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? NV3hd|NKOjR{NECyNFM>
UoCB6 Ml2wSpVv[3Srb36gRZN{[Xl? NF3vWJM2NzFyIN88US=> NFfRemNt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= MmH1NlQzPDB{MEO=
AT2 NYPqbWdwS2WubDDWbYFjcWyrdImgRZN{[Xl? MXuwMVI2KM7:TR?= M{Wz[IlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? M3njZlI1OjRyMkCz
REH M4TZXWNmdGxiVnnhZoltcXS7IFHzd4F6 M2TlZVAuOjVizszN M3HP[4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NIqyXFgzPDJ2MEKwNy=>
UoCB6 Mn:0R4VtdCCYaXHibYxqfHliQYPzZZk> MViwMVI2KM7:TR?= M{\rXYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? MkjtNlQzPDB{MEO=
A2780 MVTGeY5kfGmxbjDBd5NigQ>? MmXSOU8yOC9{MDFOwG0> M3fyTlI1KGh? MYj1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? NVP4d4hGOjRzM{[xOFc>
H460 MUjGeY5kfGmxbjDBd5NigQ>? NVTmdoY{PS9zMD:yNEDPxE1? MXiyOEBp NULMfXBOfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= NEPUO2UzPDF|NkG0Oy=>
Lovo  MoDjSpVv[3Srb36gRZN{[Xl? NVm4U5l[PS9zMD:yNEDPxE1? NUjzVVA5OjRiaB?= MmCweZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? MVWyOFE{PjF2Nx?=
A2780 NH\MUXVCeG:ydH;zbZMhSXO|YYm= NGrU[Gs2NzFyL{KwJO69VQ>? MYmyOEBp Mlna[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> M3fibVI1OTN4MUS3
H460 NEnr[2hCeG:ydH;zbZMhSXO|YYm= NIHBR|I2NzFyL{KwJO69VQ>? MlzHNlQhcA>? Mmnk[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> NXLLUIRkOjRzM{[xOFc>
Lovo  NYiwUllZSXCxcITvd4l{KEG|c3H5 NEXmeYw2NzFyL{KwJO69VQ>? M1nEUVI1KGh? MX\lcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> NFrWeogzPDF|NkG0Oy=>

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID